Time-of-Day of Initial Immune Checkpoint Inhibitor Administration and Its Impact on Outcomes in Metastatic Non-Small Cell Lung Cancer.
PURPOSE Immune checkpoint inhibitors (ICIs) are integral to first-line treatment of metastatic non-small cell lung cancer (NSCLC). Circadian biology may influence antitumor immunity, raising the hypothesis that time-of-day of ICI administration could affect outcomes. We evaluated the association between initial and cum...